Alnylam Pharmaceuticals (ALNY) Equity Average (2010 - 2026)

Alnylam Pharmaceuticals (ALNY) has 17 years of Equity Average data on file, last reported at $932.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 278.03% year-over-year to $932.3 million; the trailing twelve-month figure through Mar 2026 stood at $932.3 million (up 278.03% YoY), and the FY2025 full-year result was $428.1 million, up 657.62% from the prior year.
• Equity Average for Q1 2026 stood at $932.3 million, up from $511.5 million in the prior quarter.
• Across five years, Equity Average topped out at $932.3 million in Q1 2026 and bottomed at -$333.7 million in Q2 2023.
• The 5-year median for Equity Average is $49.7 million (2024), against an average of $100.4 million.
• The widest annual swing landed in 2023, when Equity Average slumped 629.51%; it then surged 1554.27% in 2025.
• A 5-year view of Equity Average shows it stood at -$112.9 million in 2022, then plunged by 71.13% to -$193.3 million in 2023, then jumped by 125.73% to $49.7 million in 2024, then jumped by 928.81% to $511.5 million in 2025, then jumped by 82.25% to $932.3 million in 2026.
• The last three Equity Average figures came in at $932.3 million (Q1 2026), $511.5 million (Q4 2025), and $242.2 million (Q3 2025), per Business Quant data.

Peer Comparison